|
시장보고서
상품코드
2008986
종양용해성 바이러스 치료 시장 보고서 : 바이러스 유형별, 용도별, 최종 용도별, 지역별(2026-2034년)Oncolytic Virus Therapies Market Report by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses), Application (Solid Tumors, Melanoma), End Use (Hospitals, Specialty Clinics, Cancer Research Institute), and Region 2026-2034 |
||||||
세계의 종양용해성 바이러스 치료 시장 규모는 2025년에 2억 2,200만 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 8억 1,540만 달러에 달하고, 2026년부터 2034년까지 CAGR 15.09%로 성장할 것으로 예측했습니다.
종양용해성 바이러스 치료는 바이러스를 이용해 암세포를 감염시켜 파괴하는 면역치료의 일종입니다. 헤르페스 바이러스, 뉴캐슬병 바이러스, 백시니아 바이러스, 아데노 바이러스, 레오 바이러스, 피콜로나 바이러스 등 다양한 천연 및 유전자 재조합 바이러스가 사용됩니다. 종양용해성 바이러스 치료는 면역 반응을 유도하는 위험 신호를 활성화하여 고형 종양, 악성 흑색종 및 절제 불가능한 병변을 치료하는 데 널리 사용되고 있습니다. 또한, 표적 종양세포만을 감염, 파괴하는 바이러스를 이용하여 종양의 근절에도 기여합니다. 화학요법에 비해 종양용해성 바이러스 치료은 독성이 없고, 우수한 효능을 나타내며, 암 환자의 생존기간을 연장시킵니다. 그 결과, 병원, 진료소 및 암 연구기관에서 폭넓게 적용되고 있습니다.
종양용해성 바이러스 치료 시장 동향:
전 세계적으로 암 발생률이 증가하고 있는 것이 이 시장의 전망을 밝게 하고 있습니다. 종양용해성 바이러스 치료는 강력한 항종양 특성과 주변 조직을 손상시키지 않고 종양을 정확하게 표적으로 삼는 능력으로 인해 교모세포종, 유방암, 폐암, 전립선암 등 다양한 암 치료에 널리 사용되고 있습니다. 이에 따라 혈액암, 림프종, 백혈병, 다발성 골수종 등 다양한 종류의 악성 종양 치료에 광범위하게 사용되면서 시장 성장을 견인하고 있습니다. 또한, 외과적 개입, 방사선 치료, 화학요법, 면역요법 등 다양한 암 치료법이 건강에 미치는 악영향에 대한 환자들의 우려가 커지면서 시장 성장에 큰 탄력을 받고 있습니다. 또한, 헤르페스 바이러스, 아데노 바이러스, 백시니아 바이러스 등 종양용해성 바이러스에 대한 임상연구가 마무리 단계에 있으며, 우수한 실험결과를 보이고 있어 시장 성장을 견인하고 있습니다. 이 외에도 첨단 치료법 및 새로운 치료법에 대한 수요 증가, 각국 정부의 암의 다양한 원인에 대한 인식 제고 및 조기 진단을 촉진하기 위한 노력 증가 등이 시장 성장을 견인할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 종양용해성 바이러스 치료 시장
제6장 시장 내역 : 바이러스 유형별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 최종사용별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSMThe global oncolytic virus therapies market size reached USD 222.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 815.4 Million by 2034, exhibiting a growth rate (CAGR) of 15.09% during 2026-2034.
Oncolytic virus therapies are a form of immunotherapy that utilizes viruses to infect and destroy cancer cells. They use various natural and genetically modified viruses, such as herpes simplex, Newcastle disease, vaccinia, adenovirus, reovirus, and picornavirus. Oncolytic virus therapies activate danger signals for generating an immune response and are widely used for treating solid tumors, melanoma, and unresectable lesions. They also help eradicate tumors using viruses that only infect and destroy targeted tumor cells. As compared to chemotherapy, oncolytic virus therapies are non-toxic, provide superior efficacy, and prolong the survival of cancer patients. As a result, they find extensive applications in hospitals, clinics, and cancer research institutes.
ONCOLYTIC VIRUS THERAPIES MARKET TRENDS:
The rising incidences of cancer across the globe are creating a positive outlook for the market. Oncolytic virus therapies are widely used to treat various cancers, such as glioblastoma, breast, lung, and prostate cancers, due to their powerful anti-tumor properties and ability to target tumors accurately without harming surrounding tissues. In line with this, the widespread utilization of the therapy to treat various types of melanomas, such as hematological malignancies, lymphoma, leukemia, and myeloma, is favoring the market growth. Furthermore, rising concerns among patients regarding the negative health impact of various cancer treatments, such as surgical intervention, radiotherapy , chemotherapy, and immunotherapy, are providing a considerable boost to the market growth. Additionally, the rising number of clinical studies in oncolytic viruses, such as herpesvirus, adenovirus, and vaccinia virus, that is in the final stages and have demonstrated excellent experimental results are facilitating the market growth. Other factors, including rising demand for advanced treatments and novel therapies and increasing initiatives by several governments to spread awareness regarding different causes of cancer and promote early diagnosis, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Breakup by Virus Type:
- Genetically Engineered Oncolytic Viruses
- Herpes Simplex Virus
- Adenovirus
- Vaccinia Virus
- Oncolytic Wild-Type Viruses
- Reovirus
- Newcastle Disease Virus
- Vesicular Stomatitis Virus
Breakup by Application:
- Solid Tumors
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Glioblastoma
- Melanoma
- Hematological Malignancies
- Lymphoma
- Leukemia
- Myeloma
Breakup by End Use:
- Hospitals
- Specialty Clinics
- Cancer Research Institute
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Dnatrix Inc., Genelux Corporation, Lokon Pharma AB, Replimune Group Inc., Rigvir Ltd., Sorrento Therapeutics, Takara Bio Inc. (Takara Holdings Inc.), Targovax, TILT Biotherapeutics Ltd, Transgene SA and Vyriad. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. What was the size of the global oncolytic virus therapies market in 2025?
2. What is the expected growth rate of the global oncolytic virus therapies market during 2026-2034?
3. What are the key factors driving the global oncolytic virus therapies market?
4. What has been the impact of COVID-19 on the global oncolytic virus therapies market?
5. What are the key regions in the global oncolytic virus therapies market?
6. Who are the key players/companies in the global oncolytic virus therapies market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Oncolytic Virus Therapies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Virus Type
- 6.1 Genetically Engineered Oncolytic Viruses
- 6.1.1 Market Trends
- 6.1.2 Key Segments
- 6.1.2.1 Herpes Simplex Virus
- 6.1.2.2 Adenovirus
- 6.1.2.3 Vaccinia Virus
- 6.1.3 Market Forecast
- 6.2 Oncolytic Wild-Type Viruses
- 6.2.1 Market Trends
- 6.2.2 Key Segments
- 6.2.2.1 Reovirus
- 6.2.2.2 Newcastle Disease Virus
- 6.2.2.3 Vesicular Stomatitis Virus
- 6.2.3 Market Forecast
7 Market Breakup by Application
- 7.1 Solid Tumors
- 7.1.1 Market Trends
- 7.1.2 Key Segments
- 7.1.2.1 Breast Cancer
- 7.1.2.2 Prostate Cancer
- 7.1.2.3 Lung Cancer
- 7.1.2.4 Glioblastoma
- 7.1.3 Market Forecast
- 7.2 Melanoma
- 7.2.1 Market Trends
- 7.2.2 Key Segments
- 7.2.2.1 Hematological Malignancies
- 7.2.2.2 Lymphoma
- 7.2.2.3 Leukemia
- 7.2.2.4 Myeloma
- 7.2.3 Market Forecast
8 Market Breakup by End Use
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Cancer Research Institute
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Amgen Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Dnatrix Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Genelux Corporation
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.4 Lokon Pharma AB
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Replimune Group Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.6 Rigvir Ltd.
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.7 Sorrento Therapeutics
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.8 Takara Bio Inc. (Takara Holdings Inc.)
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.9 Targovax
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 TILT Biotherapeutics Ltd
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.11 Transgene SA
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.12 Vyriad
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.1 Amgen Inc.
